These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 1686385)

  • 1. Pleuropulmonary disease associated with dopamine agonist therapy.
    Bhatt MH; Keenan SP; Fleetham JA; Calne DB
    Ann Neurol; 1991 Oct; 30(4):613-6. PubMed ID: 1686385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pleuropulmonary changes during treatment of Parkinson's disease with a long-acting ergot derivative, cabergoline.
    Frans E; Dom R; Demedts M
    Eur Respir J; 1992 Feb; 5(2):263-5. PubMed ID: 1348483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pleuropulmonary disease during bromocriptine treatment of Parkinson's disease.
    McElvaney NG; Wilcox PG; Churg A; Fleetham JA
    Arch Intern Med; 1988 Oct; 148(10):2231-6. PubMed ID: 3178380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Constrictive pericarditis and pleuropulmonary disease linked to ergot dopamine agonist therapy (cabergoline) for Parkinson's disease.
    Ling LH; Ahlskog JE; Munger TM; Limper AH; Oh JK
    Mayo Clin Proc; 1999 Apr; 74(4):371-5. PubMed ID: 10221467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease.
    Antonini A; Poewe W
    Lancet Neurol; 2007 Sep; 6(9):826-9. PubMed ID: 17706566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pleuropulmonary fibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson Disease.
    Tintner R; Manian P; Gauthier P; Jankovic J
    Arch Neurol; 2005 Aug; 62(8):1290-5. PubMed ID: 16087771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiac and noncardiac fibrotic reactions caused by ergot-and nonergot-derived dopamine agonists.
    Andersohn F; Garbe E
    Mov Disord; 2009 Jan; 24(1):129-33. PubMed ID: 19170199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pleuropulmonary changes induced by ergoline drugs.
    Pfitzenmeyer P; Foucher P; Dennewald G; Chevalon B; Debieuvre D; Bensa P; Piard F; Camus P
    Eur Respir J; 1996 May; 9(5):1013-9. PubMed ID: 8793465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pleuro-pulmonary changes after bromocriptine treatment of parkinsonism].
    Bøttcher J; Grøn U
    Ugeskr Laeger; 1981 Oct; 143(41):2648-9. PubMed ID: 7303288
    [No Abstract]   [Full Text] [Related]  

  • 10. Update on dopamine agonists in Parkinson's disease: "beyond bromocriptine".
    Lang AE
    Can J Neurol Sci; 1987 Aug; 14(3 Suppl):474-82. PubMed ID: 3315148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Acute pleuropulmonary complication following an injection of an anti-inflammatory agent].
    Brodersen HC; Lang KF; Bose E; Schuster HP; Just HG
    Poumon Coeur; 1970; 26(9):1075-8. PubMed ID: 5518899
    [No Abstract]   [Full Text] [Related]  

  • 12. Pergolide-induced pleuropulmonary fibrosis.
    Bleumink GS; van der Molen-Eijgenraam M; Strijbos JH; Sanwikarja S; van Puijenbroek EP; Stricker BH
    Clin Neuropharmacol; 2002; 25(5):290-3. PubMed ID: 12410064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lisuride, a dopamine receptor agonist with 5-HT2B receptor antagonist properties: absence of cardiac valvulopathy adverse drug reaction reports supports the concept of a crucial role for 5-HT2B receptor agonism in cardiac valvular fibrosis.
    Hofmann C; Penner U; Dorow R; Pertz HH; Jähnichen S; Horowski R; Latté KP; Palla D; Schurad B
    Clin Neuropharmacol; 2006; 29(2):80-6. PubMed ID: 16614540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low dose cabergoline induced interstitial pneumonitis.
    Frank W; Moritz R; Becke B; Pauli R
    Eur Respir J; 1999 Oct; 14(4):968-70. PubMed ID: 10573251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Lisuride in the combination treatment of Parkinson disease].
    Jellinger K
    Wien Med Wochenschr; 1987 Apr; 137(7-8):155-9. PubMed ID: 3111099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Continuous dopaminergic stimulation in Parkinson disease].
    Obeso JA; Luquin MR; Vaamonde J; Grandas F; Pastor MA; Artieda J; Martínez-Lage JM
    Neurologia; 1987; 2(5):227-34. PubMed ID: 2908545
    [No Abstract]   [Full Text] [Related]  

  • 17. [Pleural effusion and pulmonary hypertension in a patient with Parkinson disease treated with cabergoline].
    Haro-Estarriol M; Sabater-Talaverano G; Rodríguez-Jerez F; Obrador-Lagares A; Genís-Batlle D; Sendra-Salillas S
    Arch Bronconeumol; 2009 Feb; 45(2):100-2. PubMed ID: 19232272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison between lergotrile and bromocriptine in parkinsonism.
    Teychenne PF; Pfeiffer RF; Bern SM; McInturff D; Calne DB
    Ann Neurol; 1978 Apr; 3(4):319-24. PubMed ID: 666273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of lisuride in advanced Parkinson's disease. Potent dopamine and serotonin agonist.
    Lieberman AN; Goldstein M; Neophytides A; Leibowitz M; Gopinathan G; Goodgold A; Pact V; Walker R
    N Y State J Med; 1981 Nov; 81(12):1751-5. PubMed ID: 6949052
    [No Abstract]   [Full Text] [Related]  

  • 20. Initiating treatment for idiopathic parkinsonism.
    Calne DB
    Neurology; 1994 Jul; 44(7 Suppl 6):S19-22. PubMed ID: 7914010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.